Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. raised its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 45.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 534,461 shares of the biopharmaceutical company’s stock after buying an additional 165,781 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Intra-Cellular Therapies were worth $44,638,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. M&T Bank Corp raised its position in Intra-Cellular Therapies by 2.2% during the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after acquiring an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 141 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 150 shares during the period. Pallas Capital Advisors LLC lifted its position in shares of Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 192 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Intra-Cellular Therapies by 0.8% during the 4th quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock valued at $2,302,000 after buying an additional 206 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The stock has a 50 day moving average price of $131.73 and a 200 day moving average price of $112.15.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ITCI shares. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.